ANP 11.1% 3.0¢ antisense therapeutics limited

PJ Trainer Endo 2105

  1. 4,149 Posts.
    Professor Trainer to present on atl1103
    https://endo.confex.com/endo/2015endo/webprogram/Paper20897.html
    "This study provides proof-of-concept that ATL1103 is able to significantly lower IGF-I in patients with acromegaly and offers a novel therapeutic approach."
    ....and no wonder after maintaining a 20% igf-1 reduction 2 complete months after dosing ended.
    Now you can stamp your feet and jump up and down all you like, post lots of rubbish about marketing this and marketing that, but its all irrelevant at this point in time. Atl1103 will be a new novel therapy and when they have deal signed you will all know about it.
    The guidance has been given and until they a) either sign a deal/receive a t/o bid, or b) adjust the expected timeline , then everything is as it should be with the expectation that a deal will be signed in the very immediate short term.
 
watchlist Created with Sketch. Add ANP (ASX) to my watchlist
(20min delay)
Last
3.0¢
Change
0.00(11.1%)
Mkt cap $11.14M
Open High Low Value Volume
2.8¢ 3.0¢ 2.8¢ $6.364K 222.2K

Buyers (Bids)

No. Vol. Price($)
3 205424 2.9¢
 

Sellers (Offers)

Price($) Vol. No.
3.0¢ 69471 1
Last update - 14.19pm 14/12/2018 (20 minute delay) ?
(live)
Last
2.9¢
  Change
0.00 ( 3.57 %)
Open High   Low Volume
2.8¢ 2.9¢   2.8¢ 32100
Last updated 12.56pm 14/12/2018 (live) ?
ANP (ASX) Chart
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.